On the verge of RSV disease prevention: A communications toolkit
Use these materials to raise awareness about new immunisation products to protect infants in early life from a top cause of severe respiratory infections in children.
Temporal Trends in Respiratory Infection Epidemics Among Pediatric Inpatients Throughout the Course of the COVID-19 Pandemic From 2018 to 2023 in Fukushima Prefecture, Japan
Strengthening of nonpharmaceutical interventions changed the epidemic dynamics of pediatric infectious diseases, with a trend toward older hospitalized children.
A 24-month National Cohort Study examining long-term effects of COVID-19 in children and young people
Some children and young people (CYP) infected with SARS-COV-2 experience impairing symptoms post-infection, known as post-COVID-19 condition (PCC).
Health systems need to use the new tools to address RSV, a leading cause of baby hospitalisations
From being a largely unknown pathogen, RSV is now almost a household word. New solutions, such as long-acting monoclonal antibodies and maternal vaccination, both recently recommended by WHO, could dramatically alter the RSV landscape.
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, next steps are outlined to minimise the delay.
Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children — Yukon-Kuskokwim Delta Region, Alaska, October 2023–June 2024
Respiratory syncytial virus (RSV) is a leading cause of hospitalization among young children. Historically, American Indian and Alaska Native (AI/AN) children have experienced high rates of RSV-associated hospitalization.
Severe Neurological Complications With Influenza in Vietnamese Children
Influenza is a common contagious respiratory virus that primarily causes respiratory tract infections.
Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting
This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTI) in a large primary care network in Spain.
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus
Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory infection in young children.
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Conclusions
Conclusions by Peter Openshaw, Co-Chair of the the ESWI Respiratory Virus Summit 2024
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Science Policy Interface debate
How to ensure/prepare for access to immunisation programmes
